Search
Lilly and Superluminal Ink $1.3 Billion Deal for Obesity Drug Development
2025-08-15 /
Read about 0 minute
Author：小编
Eli Lilly and Company has sealed a $1.3 billion partnership with Superluminal Medicines to jointly develop small molecule drugs targeting GPCRs associated with cardiometabolic diseases and obesity. This collaboration leverages Superluminal's innovative drug discovery platform and Lilly's extensive experience in small molecule drug development, aiming to expedite the creation of potentially transformative therapies. Superluminal's oral obesity drug is anticipated to commence human trials in the upcoming year.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
